Patient baseline characteristics
| Characteristic . | PTCy (n = 112) . | Tac/Sir (n = 95) . | Tac/MTX (n = 98) . |
|---|---|---|---|
| Age, median (range), y | 56 (7-75) | 44 (18-60) | 41 (12-58) |
| Sex, n (%) | |||
| Male | 71 (63%) | 46 (48%) | 54 (55%) |
| Female | 41 (37%) | 49 (52%) | 44 (45%) |
| Year of HCT, range | 2013-2016 | 2007-2011 | 2006-2011 |
| Primary disease, n (%) | |||
| AML | 48 (43%) | 43 (45%) | 40 (41%) |
| MDS | 15 (13%) | 11 (12%) | 5 (5%) |
| ALL | 11 (10%) | 33 (35%) | 45 (46%) |
| Other | 38 (34%) | 8 (8%) | 8 (8%) |
| Conditioning intensity, n (%) | |||
| MA | 43 (38%) | 95 (100%) | 98 (100%) |
| RIC | 20 (18%) | 0 | 0 |
| NMA | 49 (44%) | 0 | 0 |
| Donor type, n (%) | |||
| Matched related donor | 15 (13%) | 95 (100%) | 95 (100%) |
| Unrelated donor | 22 (20%) | 0 | 0 |
| Haploidentical donor | 75 (67%) | 0 | 0 |
| Graft type, n (%) | |||
| Bone marrow | 39 (35%) | 0 | 0 |
| Peripheral blood | 73 (65%) | 95 (100%) | 98 (100%) |
| Characteristic . | PTCy (n = 112) . | Tac/Sir (n = 95) . | Tac/MTX (n = 98) . |
|---|---|---|---|
| Age, median (range), y | 56 (7-75) | 44 (18-60) | 41 (12-58) |
| Sex, n (%) | |||
| Male | 71 (63%) | 46 (48%) | 54 (55%) |
| Female | 41 (37%) | 49 (52%) | 44 (45%) |
| Year of HCT, range | 2013-2016 | 2007-2011 | 2006-2011 |
| Primary disease, n (%) | |||
| AML | 48 (43%) | 43 (45%) | 40 (41%) |
| MDS | 15 (13%) | 11 (12%) | 5 (5%) |
| ALL | 11 (10%) | 33 (35%) | 45 (46%) |
| Other | 38 (34%) | 8 (8%) | 8 (8%) |
| Conditioning intensity, n (%) | |||
| MA | 43 (38%) | 95 (100%) | 98 (100%) |
| RIC | 20 (18%) | 0 | 0 |
| NMA | 49 (44%) | 0 | 0 |
| Donor type, n (%) | |||
| Matched related donor | 15 (13%) | 95 (100%) | 95 (100%) |
| Unrelated donor | 22 (20%) | 0 | 0 |
| Haploidentical donor | 75 (67%) | 0 | 0 |
| Graft type, n (%) | |||
| Bone marrow | 39 (35%) | 0 | 0 |
| Peripheral blood | 73 (65%) | 95 (100%) | 98 (100%) |
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MA, myeloablative; MDS, myelodysplastic syndrome; NMA, non-myeloablative; RIC, reduced intensity conditioning.